Logo Image
|Articles|July 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-07-01-2001
  • Volume 0
  • Issue 0

A Giant Stumbles

Author(s)Kevin Gopal

Basel, Switzerland—Roche, which recently slashed its work force by 3,000, maintains that it will remain independent even after the sale of 20 percent of the company to Novartis. Franz Humer, the troubled company’s chairman, says the founding family supports Roche’s strategy.

Articles in this issue

over 25 years ago

Pharmacies: OTC Price Wars

over 25 years ago

One Disease at a Time

over 25 years ago

Overview of the Industry: A World of Opportunities

over 25 years ago

The Power Shift

over 25 years ago

Overruled: No More Dual Pricing

over 25 years ago

Submerged

over 25 years ago

Generic Threat

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more